Stina Söderlund

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients

Luukkainen, Katariina; Purhonen, Mikko; Tatun, Mikael; Hung, Kevin et al.

Part of HemaSphere, 2026

• DOI for Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients
• Download full text (pdf) of Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients

Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Purhonen, Mikko; Tatun, Mikael; Luukkainen, Katariina; Hung, Kevin et al.

Part of Leukemia, p. 2968-2977, 2025

• DOI for Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML
• Download full text (pdf) of Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Flygt, Hjalmar; Söderlund, Stina; Richter, Johan; Saussele, Susanne et al.

Part of Leukemia, p. 781-787, 2024

• DOI for Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
• Download full text (pdf) of Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Iribarren, Cristina; Levedahl, Kerstin; Atanasoai, Ionut; Mattsson, Mattias et al.

Part of Journal of Molecular Diagnostics, p. 792-804, 2024

• DOI for Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
• Download full text (pdf) of Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis

Söderlund, Stina; Boey, Daryl; van Midden, Wouter; Kjellander, Matilda et al.

Part of Journal of Allergy and Clinical Immunology, p. 205-213, 2023

• DOI for Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients

Luukkainen, Katariina; Purhonen, Mikko; Tatun, Mikael; Hung, Kevin et al.

Part of HemaSphere, 2026

• DOI for Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients
• Download full text (pdf) of Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients

Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Purhonen, Mikko; Tatun, Mikael; Luukkainen, Katariina; Hung, Kevin et al.

Part of Leukemia, p. 2968-2977, 2025

• DOI for Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML
• Download full text (pdf) of Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Flygt, Hjalmar; Söderlund, Stina; Richter, Johan; Saussele, Susanne et al.

Part of Leukemia, p. 781-787, 2024

• DOI for Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
• Download full text (pdf) of Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Iribarren, Cristina; Levedahl, Kerstin; Atanasoai, Ionut; Mattsson, Mattias et al.

Part of Journal of Molecular Diagnostics, p. 792-804, 2024

• DOI for Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
• Download full text (pdf) of Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis

Söderlund, Stina; Boey, Daryl; van Midden, Wouter; Kjellander, Matilda et al.

Part of Journal of Allergy and Clinical Immunology, p. 205-213, 2023

• DOI for Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Dolinska, Monika; Cai, Huan; Mansson, Alma; Shen, Jingyi et al.

Part of Blood, p. 73-89, 2023

• DOI for Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
• Download full text (pdf) of Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Huuhtanen, Jani; Ilander, Mette; Yadav, Bhagwan; Dufva, Olli M. J. et al.

Part of Journal of Clinical Investigation, 2022

• DOI for IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
• Download full text (pdf) of IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Flygt, Hjalmar; Söderlund, Stina; Stentoft, Jesper; Richter, Johan et al.

Part of European Journal of Haematology, p. 617-623, 2021

• DOI for Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
• Download full text (pdf) of Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Flygt, Hjalmar; Sandin, Fredrik; Dahlén, Torsten; Dremaine, Arta et al.

Part of British Journal of Haematology, p. 915-921, 2021

• DOI for Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
• Download full text (pdf) of Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI

Richter, Johan; Lübking, Anna; Söderlund, Stina; Lotfi, Kourosh et al.

Part of Leukemia, p. 2416-2418, 2021

• DOI for Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI
• Download full text (pdf) of Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Söderlund, Stina; Persson, Inger; Ilanderd, Mette; Guilhot, Joelle et al.

Part of Leukemia Research, 2020

• DOI for Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

Grootens, Jennine; Ungerstedt, Johanna S.; Ekoff, Maria; Rönnberg, Elin et al.

Part of EBioMedicine, p. 150-158, 2019

• DOI for Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
• Download full text (pdf) of Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Kreutzman, Anna; Yadav, Bhagwan; Brummendorf, Tim H.; Gjertsen, Bjorn Tore et al.

Part of Oncoimmunology, 2019

• DOI for Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
• Download full text (pdf) of Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander, M; Olsson-Strömberg, Ulla; Schlums, H; Guilhot, J et al.

Part of Leukemia, p. 1108-1116, 2017

• DOI for Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
• Download full text (pdf) of Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era: a report from the Swedish CML register

Söderlund, Stina; Dahlén, Torsten; Sandin, Fredrik; Olsson-Strömberg, Ulla et al.

Part of European Journal of Haematology, p. 57-66, 2017

• DOI for Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era: a report from the Swedish CML register

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik et al.

Part of Leukemia Research, p. 95-103, 2016

• DOI for Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Plasma Proteomics In Chronic Myeloid Leukemia Patients Before And After Initiation Of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity And Loss Of Angiogenic Stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, H. et al.

Part of Haematologica, p. 730-730, 2016

In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients

Skoglund, Karin; Richter, Johan; Olsson-Strömberg, Ulla; Bergquist, Jonas et al.

Part of Therapeutic Drug Monitoring, p. 230-238, 2016

• DOI for In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Christiansson, Lisa; Söderlund, Stina; Mangsbo, Sara; Hjorth-Hansen, Henrik et al.

Part of Molecular Cancer Therapeutics, p. 1181-1191, 2015

• DOI for The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta et al.

Part of European Journal of Haematology, p. 243-250, 2015

• DOI for Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
• Download full text (pdf) of Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

PROGRESSION OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO ADVANCED PHASE ON TKI THERAPY: A POPULATION BASED ANALYSIS FROM THE SWEDISH CML REGISTER

Söderlund, Stina; Dahlen, T.; Creignou, M.; Sandin, F. et al.

Part of Haematologica, p. 233-233, 2015

Mature, Adaptive-like CD56(DIM) NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Ilander, Mette; Schlums, Heinrich; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna et al.

Part of Blood, 2015

Disease Relapse After Tyrosine Kinase Inhibitor Treatment Discontinuation in Chronic Myeloid Leukaemia is Related to Both Low Number and Impaired Function of NK Cells

Ilander, Mette; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna; Kasanen, Tiina et al.

Part of Scandinavian Journal of Immunology, p. 467-468, 2014

Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Richter, Johan; Söderlund, Stina; Lübking, Anna; Dreimane, Arta et al.

Part of Journal of Clinical Oncology, p. 2821-2823, 2014

• DOI for Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Ilander, Mette Matilda; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna; Tiina, Kasanen et al.

Part of Blood, 2014

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Christiansson, Lisa; Söderlund, Stina; Svensson, Emma; Mustjoki, Satu et al.

Part of PLOS ONE, 2013

• DOI for Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
• Download full text (pdf) of Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Clinical and Immunological Studies in Chronic Myeloid Leukaemia

Söderlund, Stina

2017

• Download full text (pdf) of Clinical and Immunological Studies in Chronic Myeloid Leukaemia